Scaling of ATMPs: what works, what doesn’t and what’s next
We bring together leading experts from industry, academia, healthcare and regulatory authorities to explore one of the most pressing questions facing the field today: what does it take to scale ATMPs sustainably, efficiently and successfully?
- March 24, 2027
- Corpus, Oegstgeest
- Organised by Progress – Experts in Life Sciences
March 24, 2027
Corpus, Oegstgeest
>8 experts
6 talks + panel discussion
Lunch & drinks
One day across the ATMP scaling journey
From development and manufacturing to quality, regulatory and commercialisation, scaling ATMPs requires collaboration across the value chain. Discover practical experiences, lessons learned and perspectives on where the field is heading next.
Scaling production & innovation
How can ATMP manufacturing move from successful development to robust, scalable production? Explore approaches, technologies and lessons learned from scaling processes in practice.
CMC strategy
CMC strategy needs to be carefully tied in during the development to enable fast scaling of analytical methods, QC and process. So to support the evolving larger and more complex ATMP manufacturing needs.
From development to translation
What works when moving from promising development work towards clinical application and larger-scale manufacturing? Learn from experiences across the translational journey and the challenges along the way.
Regulatory outlook for scaling
Regulatory expectations continue to evolve as the ATMP field matures. Explore current developments, practical challenges and what may be next for developers and manufacturers preparing to scale.
Full day program
Talks, a panel discussion and plenty of time to connect, all around one theme: scaling ATMPs.
09:00 – 09:30Registration & coffee
09:45 – 10:30Hospital Innovation to Scalable ATMP Model: CAR-T in Autoimmune DiseaseRosa de Groot, Somayeh Rezaeifard
Dr. Rosa de GrootAssociate Professor & Head of the Translational Research Laboratory, Department of Hematology, LUMC
Somayeh Rezaeifard, Ph.D.Clinical Account Manager, Cell and Gene Therapy, Miltenyi Biotec
10:30 – 11:15ATMP regulatory updateFrank van Engelenburg, Cor Marsman
Frank van Engelenburg, Ph.D.Managing Consultant, Progress – Experts in Life Sciences
Cor Marsman, Ph.D.Managing Consultant, Progress – Experts in Life Sciences
11:15 – 11:45Break
12:30 – 13:30Lunch
13:30 – 13:45Reflection and resetCor Marsman
Cor Marsman, Ph.D.Managing Consultant, Progress – Experts in Life Sciences
14:30 – 15:15CMC strategy for gene therapiesKarin Hoogendoorn
Karin Hoogendoorn, PharmDSenior Director CMC, Genewity
15:15 – 15:45Break
15:45 – 16:30Oncolytic mRNA therapeutics and its manufacturing challengesMarian Kupculak, Katka Franke
Marian Kupculak, DPhilChief Science Officer and Co-Founder, Sensible Biotechnologies IncChallenges in mRNA manufacturing: Why is mRNA sequence alone not sufficient to bring the new therapeutics into the market
Katka Franke, PharmD, PhDSenior Director Cancer Antigen Discovery and Validation and Managing Director, From promise to precision: selecting targets for mRNA cancer vaccines
17:00 – 18:30Drinks & networking
Meet the speakers
Dr. Rosa de Groot
Associate Professor & Head of the Translational Research Laboratory, Department of Hematology
Rosa is Associate Professor and Head of the Translational Research Laboratory within the Department of Hematology at LUMC. Her research focuses on immunotherapy and the development of next-generation cell therapies, with a particular emphasis on T-cell and NK-cell based approaches for cancer treatment. Rosa has extensive experience spanning academia, translational research, and clinical application, having previously held research positions at the Oncode Institute and Sanquin. She is widely recognized for her contributions to tumor-reactive T cell discovery and the advancement of engineered immune cell therapies for oncology.
For this year’s summit, Rosa will join forces with Miltenyi Biotec for a joint presentation as part of our theme “Scaling of ATMPs: what works, what doesn’t and what’s next.”
We are very much looking forward to welcoming Rosa and hearing her perspective on one of the key challenges facing the ATMP field today.
Somayeh Rezaeifard, Ph.D.
Clinical Account Manager, Cell and Gene Therapy
Somayeh has a strong background in cell therapy, immunology and translational research. Her experience spans both scientific research and the application of innovative approaches in the field of cellular therapies.
For this year’s summit, Somayeh will join Rosa de Groot for a joint presentation as part of our theme “Scaling of ATMPs: what works, what doesn’t and what’s next.”
We are very much looking forward to welcoming Somayeh and having her perspective as part of the programme.
Cor Marsman, Ph.D.
Managing Consultant
For this year’s summit, Cor will provide an ATMP regulatory update as part of our theme “Scaling of ATMPs: what works, what doesn’t and what’s next.”
With his extensive experience in QA, regulatory and ATMPs, Cor will share his perspective on the evolving regulatory landscape and its relevance for organisations developing and scaling advanced therapies.
We are very much looking forward to welcoming Cor and having his experience and perspective as part of the programme.
Frank van Engelenburg, Ph.D.
Managing Consultant
For this year’s summit, Frank will share his perspective on CMC and the development of ATMPs as part of our theme “Scaling of ATMPs: what works, what doesn’t and what’s next.”
Drawing on his extensive experience in CMC development of biologicals, vaccines and gene therapy products, Frank will bring a practical perspective on the challenges and considerations involved in taking advanced therapies further through development.
We are very much looking forward to welcoming Frank and having his expertise as part of the programme.
Katka Franke, PharmD, PhD
Senior Director Cancer Antigen Discovery and Validation and Managing Director
Katka obtained her PhD in Immunology from the VU University in Amsterdam and continued her academic career for several years in the field of immune-oncology. After that, she transitioned to industry and her first role was as oncology drug development consultant, assisting start-ups and small biotech companies to launch their pre-clinical projects into first-in-human studies. In 2020 she joined a start-up company Frame Therapeutics, where her major responsibility was to establish in-house immunology research into tumor neoantigens identified through a proprietary genomic and bioinformatics pipeline. Frame Therapeutics was acquired in July 2022 by CureVac, the global mRNA company. Her latest position in the company was Senior Director Cancer Antigen Discovery and Validation and Managing Director of CureVac Netherlands.
For this year’s summit, Katka will present as part of our theme “From promise to precision: selecting targets for mRNA cancer vaccines.”
We are very much looking forward to welcoming Katka and having her perspective as part of the programme.
Marian Kupculak, DPhil
Chief Science Officer and Co-Founder
Marian obtained his DPhil in Biochemistry at the University of Oxford, where he studied genomic stability, and protein–nucleic acid interactions. After receiving his degree, he co-founded Sensible Biotechnologies and became Chief Scientific Officer. Sensible Biotechnologies is pioneering a novel method to design and manufacture mRNA therapeutic in living cells, leading to increased mRNA purity, lower immunogenicity, and decreased manufacturing costs. Since its beginning, Sensible has raised over $50M in private investments and non-dilute fundings, and is currently operating in the US, UK and Slovakia.
For this year’s summit, Marian will present as part of our theme “Challenges in mRNA manufacturing: Why is mRNA sequence alone not sufficient to bring the new therapeutics into the market.”
We are very much looking forward to welcoming Marian and having his perspective as part of the programme.
Karin Hoogendoorn, PharmD
Senior Director CMC
Karin Hoogendoorn, PharmD is Senior Director CMC at Genewity, where she leads the CMC strategy for an ex vivo gene therapy product in development. With more than 25 years of experience across the cell and gene therapy landscape, Karin has held senior CMC and regulatory leadership roles at Genewity, Galapagos, uniQure, Lonza, Novartis, and Johnson & Johnson. She is recognized for her expertise in CMC development, manufacturing, regulatory strategy, and portfolio management for advanced therapies. Karin has also contributed to the broader ATMP field through international advisory and standardization roles, including serving as Chair of the Cell & Gene Therapy Products Committee of the International Alliance for Biological Standardization (IABS).
For this year’s summit, Karin will present as part of our theme “CMC strategy for gene therapy products.”
We are very much looking forward to welcoming Karin and having her perspective as part of the programme.
Secure your seat
Wednesday, March 24, 2027 – Corpus, Oegstgeest
Includes full access to the conference program, networking sessions, and all-day refreshments.
Now – December 1Early bird: 33% off the regular ticket – for everyone, no code needed
From December 2Regular price · partner discount unlocks
All prices are shown excl. 21% VAT. The price incl. VAT is shown in grey below each price.
Early bird · until December 1
Regular
Access for one person
excl. VAT · € 313,14 incl. VAT
For everyone – no code needed
Members of UMCs, DARQA, ISPE, HollandBio and freelancers from the Progress network
Duo rate
Duo
Access for two people
excl. VAT · € 704,16 incl. VAT
€ 290,98 per person excl. VAT
Already a reduced rate – early bird doesn’t apply
€ 261,88 per person excl. VAT
Members of UMCs, DARQA, ISPE, HollandBio and freelancers from the Progress network
Reduced rate
Student / Start-up
MSc, PhD, PostDoc or start-up
excl. VAT · € 279,51 incl. VAT
Max. 10 tickets available – be quick!
Already a reduced rate – early bird doesn’t apply
Invoice on company name available · Ticket sales close March 23, 2027 · Cancellation terms
Discounts cannot be combined.
The Dutch ATMP Summit in numbers
past attendees
speakers this edition
organisations over the years
edition
This year's edition takes place at Corpus
-
Corpus
Willem Einthovenstraat 1, 2342 BH Oegstgeest - +31 (0)23 563 5016 (Progress Head Office)
- info@dutchatmpsummit.com
From Amsterdam (A44): take exit 8A (Leiden) towards Katwijk / Noordwijk, then the first exit towards CORPUS.
From The Hague / Wassenaar (A44): take exit 8A (Leiden) towards Katwijk / Voorschoten / Noordwijk, drive under the viaduct and take the first right.
Navigation address: Willem Einthovenstraat 1, 2342 BH Oegstgeest.
Bus 9 or 38: get off at stop Willem Einthovenstraat, Oegstgeest.
Bus 90: get off at stop Corpus, Oegstgeest.
Plan your journey at 9292.nl.
Corpus has a covered parking garage (€ 12.50 per car, maximum height 2.10 m). The garage has no elevator.
Visitors with limited mobility can be dropped off at the entrance of the building.
What is the language of the summit?
The summit is held entirely in English. All presentations, panel discussions and materials are in English, so everyone in the ATMP field can take part, wherever they are based.
Can I receive an invoice on my company name?
Yes. An invoice on your company name is available for all tickets.
Can I cancel or transfer my ticket?
Tickets are personal, but if you can’t attend you are welcome to send a substitute in your place at no extra cost. Please let us know the name and email address of your replacement. Cancelling without a substitute is not eligible for a refund. If the summit is cancelled or the date changes and you can no longer attend, you will receive a full refund of your registration fee.
Are lunch and drinks included?
Yes. Your ticket includes participation in the summit, lunch, coffee and tea during the breaks, and the closing reception.
Can I indicate dietary requirements?
Yes. Please let us know about any dietary requirements or allergies when you register, or send an email to info@dutchatmpsummit.com at least 14 days before the event. We will make sure there is a suitable option for you.
Will there be photography during the event?
Yes. Photos and videos will be taken during the summit and may be used on our website, social media and other channels to promote the event. Prefer not to appear in them? Let the photographer or the registration desk know.
Who can I contact with other questions?
Our team is happy to help. Email info@dutchatmpsummit.com or call +31 (0)23 563 5016.